John C. Fang

John C. Fang

Auto-generated profile, based on publicly available information

John C. Fang

University of Utah School of Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2011 in BMC Medicine
Verified
Journal Article
Open access
PDF file
JWJorja D Warren
Jorja D Warren
WXWei Xiong
Wei Xiong
ABAshley M Bunker
Ashley M Bunker
CVCecily P Vaughn
Cecily P Vaughn
LFLarissa V Furtado
Larissa V Furtado
KHKaren A Heichman
Karen A Heichman
Background: About half of Americans 50 to 75 years old do not follow recommended colorectal cancer (CRC) screening guidelines, leaving 40 million individuals unscreened. A simple blood test would increase screening compliance, promoting early detection and better patient outcomes. The objective of this study is to demonstrate the performance of an improved sensitivity blood-based Septin 9 (SEPT9) methylated DNA test for colorectal cancer. Study variables include clinical stage, tumor location and histologic grade. Methods: Plasma samples were collected from 50 untreated CRC patients at 3 institutions; 94 control samples were collected at 4 US institutions; samples were collected from 300 colonoscopy patients at 1 US clinic prior to endoscopy. SEPT9 methylated DNA concentration was tested in analytical specimens, plasma of known CRC cases, healthy control subjects, and plasma collected from colonoscopy patients. Results: The improved SEPT9 methylated DNA test was more sensitive than previously described methods; the test had an overall sensitivity for CRC of 90% (95% CI, 77.4% to 96.3%) and specificity of 88% (95% CI, 79.6% to 93.7%), detecting CRC in patients of all stages. For early stage cancer (I and II) the test was 87% (95% CI, 71.1% to 95.1%) sensitive. The test identified CRC from all regions, including proximal colon (for example, the cecum) and had a 12% false-positive rate. In a small prospective study, the SEPT9 test detected 12% of adenomas with a false-positive rate of 3%. Conclusions: A sensitive blood-based CRC screening test using the SEPT9 biomarker specifically detects a majority of CRCs of all stages and colorectal locations. The test could be offered to individuals of average risk for CRC who are unwilling or unable to undergo colonscopy.

18 June 2009 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KPKathryn A. Peterson
Kathryn A. Peterson
KTKristen L. Thomas
Kristen L. Thomas
KHKristen Hilden
Kristen Hilden
LELyska L. Emerson
Lyska L. Emerson
JWJason C. Wills
Jason C. Wills
JFJohn C. Fang
John C. Fang

12 October 2012 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
JSJames L. Stayner
James L. Stayner
ABAkash Bhatnagar
Akash Bhatnagar
AMArlo N. McGinn
Arlo N. McGinn
JFJohn C. Fang
John C. Fang

18 April 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PLPatrick Laing
Patrick Laing
TPTuan Pham
Tuan Pham
LTLinda Jo Taylor
Linda Jo Taylor
JFJohn Fang
John Fang

1 April 2008 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PPPanagiotis H. Panagiotakis
Panagiotis H. Panagiotakis
JDJames A. DiSario
James A. DiSario
KHKristen Hilden
Kristen Hilden
MOMaydeen Ogara
Maydeen Ogara
JFJohn C. Fang
John C. Fang

24 November 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
TMTyler McVay
Tyler McVay
JFJohn C. Fang
John C. Fang
LTLinda Taylor
Linda Taylor
AAAlexander Au
Alexander Au
WWWesley Williams
Wesley Williams
AIAnna Ibele
Anna Ibele